NI-0401 in Active Crohn's Disease

Phase 1

Completed

• Conditions: Moderate to Severe Crohn's Disease
• Interventions: Drug: Placebo; Biological: NI-0401 (anti-CD3 mAB)

• Registration Number: NCT00630643
• Lead Sponsor: Light Chain Bioscience - Novimmune SA

Brief Summary

The purpose of the study is to assess the safety and tolerability of daily intravenous NI-0401 treatment, compared to matching placebo. And to assess the ability of NI-0401 to modulate the CD3 complex on T-cells.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Status Verified: 2008-02
• Study First Submitted: 2008-02-28
• Study First Submitted QC: 2008-03-06
• Last Update Submitted: 2008-03-06
• Study First Posted: 2008-03-07
• Last Update Posted: 2008-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Men and women between 18 and 70 years of age.
2. Crohn's Disease Activity Index (CDAI) between 220 and 450.
3. Raised plasma CRP level.
4. Endoscopic inflammation.
5. Crohn's disease of at least 6 months duration, with colitis, ileitis, or ileocolitis, confirmed by endoscopy and histology within 28 days of study day 1.

Main Exclusion criteria

1. Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation.

2. Concomitant disease:

   • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological or cerebral disease (including a history of seizure disorders or ongoing chronic active conditions such as chronic active hepatitis)
   • Previous diagnosis of, or known, malignancies
   • Severe infections, such as hepatitis, pneumonia or pyelonephritis, in the past three months. Less serious infections in the past 3 months, such as acute upper respiratory tract infection (colds) or uncompliant urinary tract infection are permitted at the discretion of the investigator
   • Active infection requiring antibiotic therapy
   • Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive
   • History of opportunistic infections such as herpes zoster within 2 months prior to screening, evidence of acute CMV or EBV, active Pneumocystic Carinii
   • History of active tuberculosis (TB) or currently undergoing treatment for TB. Patients with a positive TB skin test or chest x-ray are ineligible. Patients with a history of bacille Calmette Guerin (BCG) vaccination and a newly positive TB skin test or a chest X-ray showing fibrotic lesions consistent with previous TB are ineligible. The PPD skin test must be read between 48 and 72 hours
   • Stool examination positive for enteric pathogens, pathogenic ova or parasites, or Clostridium Difficile toxin within 4 weeks prior to Study Day 1

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Placebo	-
2	NI-0401 (anti-CD3 mAB)	-

Primary Outcome Measures

Name	Time	Method
Safety and tolerability of intravenous NI-0401 .	24 weeks

Secondary Outcome Measures

Name	Time	Method
Immunological response defined as the percent change in the modulation of the CD3 complex on T-cells